Recent Pfizer Press Releases

  • 8/21/19 2:00 pm EDT

    XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

    TOKYO & NEW YORK--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). The application has also been granted Priority Review, a designation given to those applications formore...
  • 8/21/19 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support Pfizer’s continuing investment in gene therapy research and development, similar to Pfizer’s Chapel Hill and Kit Creek, North Carolina research and development sites. This facility would expand the company’s presence in North Carolina, where there are currently more than 3,600more...
  • 8/20/19 7:00 am EDT

    Grants to help strengthen health systems and reduce health disparities in underserved communities in Africa, Asia and Latin America

    NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation announced today 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to infectious diseases, including the increasing threat of antimicrobial resistance (AMR), in some of the world’s most vulnerable communities. Recipients of the one-year Global Health Innovation Grants (GHIG) include partners in 12 low- and middle-income countries, that will each receive US $100,000, for a totalmore...
  • 8/2/19 6:49 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease (SCD) who were hospitalized for a vaso-occlusive crisis (VOC) and required treatment with intravenous (IV)more...
  • 8/1/19 12:15 am EDT

    Combined brand portfolio forms the world's largest over-the-counter business with leadership positions in Pain Relief, Respiratory and Vitamins, Minerals and Supplements, and Therapeutic Oral Health

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the closing of its joint venture with GlaxoSmithKline plc (NYSE: GSK) to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business with robust iconic brands. As previously announced, under the terms of the transaction, Pfizer owns a 32% equity stake in the joint venture and GSK owns 68%. The combined business, which will operate globally as GSK Consumermore...
  • 7/30/19 8:16 am EDT
    • Strengthens Pfizer’s innovative biopharmaceutical business and category leadership in Oncology
    • Expected acceleration of Pfizer’s long-term growth trajectory through new medicines, including the breakthrough combination of BRAFTOVI® and MEKTOVI®
    • Highly productive research unit in Boulder, CO now part of Pfizer’s research network
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. As Array becomes part of Pfizer, it brings an impressive existing portfolio that includes the approved combined use of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for themore...
  • 7/29/19 6:50 am EDT


    NEW YORK--(BUSINESS WIRE)--Due to today’s announcement of a proposed transaction between Pfizer and Mylan, Pfizer’s second-quarter 2019 earnings conference call with investment analysts has been rescheduled for today, July 29, 2019, at 10:30 a.m. EDT. This call was previously scheduled for Tuesday, July 30, 2019 at 10 a.m. EDT. To view and listen to the webcast and view the Performance Report, visit our web site at Information on accessing and pre-registering formore...
  • 7/29/19 6:46 am EDT
    • Second-Quarter 2019 Revenues of $13.3 Billion, Reflecting 2% Operational Growth Driven by 6% Operational Growth from Pfizer Biopharmaceuticals Group
    • Second-Quarter 2019 Reported Diluted EPS(1) of $0.89, Adjusted Diluted EPS(2) of $0.80
    • Updated 2019 Financial Guidance Primarily to Reflect the Anticipated August 1, 2019 Formation of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc(3) and the Anticipated Near-Term Completion of the Array BioPharma Inc. Acquisition
    • Announces Reverse Morris Trust Transaction to Combine Upjohn and Mylan, Creating a New Global Pharmaceutical Company


    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2019 and updated certain components of its 2019 financial guidance. Results for the second quarter of 2019 and 2018(4) are summarized below. OVERALL RESULTS                   ($ in millions, except per share amounts) Second-Quarter     Six Months   2019 2018 Change     2019 2018 Changemore...
  • 7/29/19 6:45 am EDT
    • Delivers enhanced global scale and geographic reach, including leading positions in China and other emerging markets
    • Combines Mylan’s sustainable, diverse and differentiated portfolio of medicines with Upjohn’s trusted, iconic brands
    • Creates powerful platform comprising Mylan’s pipeline engine and supply chain and Upjohn’s commercial and medical infrastructure and expertise
    • Focused on driving returns through consistent cash flow growth, an attractive dividend and shareholder-focused capital policies
    • Commitment to solid investment grade ratings
    • Domiciled in the U.S. and governed by Delaware law
    • Robert J. Coury named Executive Chairman of the new company; Michael Goettler named CEO and Rajiv Malik named President
    • Concludes work of Mylan’s Strategic Review Committee
    • Mylan and Pfizer will host Investor Conference Call, Monday, July 29, 2019 at 8:30 AM Eastern Daylight Time
    HERTFORDSHIRE, England & PITTSBURGH & NEW YORK--(BUSINESS WIRE)--Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company. Pfizermore...
  • 7/23/19 1:48 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).2 “Biosimilars like RUXIENCE have the potential to deliver real value in healthcare, improving access tomore...